🎉 M&A multiples are live!
Check it out!

Cytokinetics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cytokinetics and other public comps.

See Cytokinetics Valuation Multiples

Cytokinetics Overview

About Cytokinetics

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.


Founded

1997

HQ

United States of America
Employees

564

Financials

LTM Revenue $8.7M

LTM EBITDA -$543M

EV

$5.2B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Cytokinetics Financials

Cytokinetics has a last 12-month revenue of $8.7M and a last 12-month EBITDA of -$543M.

In the most recent fiscal year, Cytokinetics achieved revenue of $7.5M and an EBITDA of -$457M.

Cytokinetics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Cytokinetics valuation multiples based on analyst estimates

Cytokinetics P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $94.6M $7.5M $3.2M $8.7M XXX
Gross Profit -$89.5M -$146M -$323M XXX XXX
Gross Margin -95% -1942% -10070% XXX XXX
EBITDA -$332M -$457M -$534M -$543M XXX
EBITDA Margin -351% -6065% -16667% -6244% XXX
Net Profit -$215M -$389M -$526M XXX XXX
Net Margin -228% -5165% -16427% XXX XXX
Net Debt $30.2M $544M $504M XXX XXX

Financial data powered by Morningstar, Inc.

Cytokinetics Stock Performance

As of February 14, 2025, Cytokinetics's stock price is $46.

Cytokinetics has current market cap of $5.4B, and EV of $5.2B.

See Cytokinetics trading valuation data

Cytokinetics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$5.2B $5.4B XXX XXX XXX XXX $-5.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Cytokinetics Valuation Multiples

As of February 14, 2025, Cytokinetics has market cap of $5.4B and EV of $5.2B.

Cytokinetics's trades at 600.9x LTM EV/Revenue multiple, and -9.6x LTM EBITDA.

Analysts estimate Cytokinetics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Cytokinetics and 10K+ public comps

Cytokinetics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $5.2B XXX XXX XXX
EV/Revenue 1631.2x XXX XXX XXX
EV/EBITDA -9.8x XXX XXX XXX
P/E -9.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -18.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Cytokinetics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Cytokinetics Valuation Multiples

Cytokinetics's NTM/LTM revenue growth is 748%

Cytokinetics's revenue per employee for the last fiscal year averaged $13K, while opex per employee averaged $0.3M for the same period.

Over next 12 months, Cytokinetics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Cytokinetics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Cytokinetics and other 10K+ public comps

Cytokinetics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -57% XXX XXX XXX XXX
EBITDA Margin -16667% XXX XXX XXX XXX
EBITDA Growth 17% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -15919% XXX XXX XXX XXX
Revenue per Employee $13K XXX XXX XXX XXX
Opex per Employee $0.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 2306% XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 2306% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Cytokinetics Public Comps

See valuation multiples for Cytokinetics public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Cytokinetics M&A and Investment Activity

Cytokinetics acquired  XXX companies to date.

Last acquisition by Cytokinetics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Cytokinetics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Cytokinetics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Cytokinetics

When was Cytokinetics founded? Cytokinetics was founded in 1997.
Where is Cytokinetics headquartered? Cytokinetics is headquartered in United States of America.
How many employees does Cytokinetics have? As of today, Cytokinetics has 564 employees.
Who is the CEO of Cytokinetics? Cytokinetics's CEO is Mr. Robert I. Blum.
Is Cytokinetics publicy listed? Yes, Cytokinetics is a public company listed on NAS.
What is the stock symbol of Cytokinetics? Cytokinetics trades under CYTK ticker.
When did Cytokinetics go public? Cytokinetics went public in 2004.
Who are competitors of Cytokinetics? Similar companies to Cytokinetics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Cytokinetics? Cytokinetics's current market cap is $5.4B
What is the current revenue of Cytokinetics? Cytokinetics's last 12-month revenue is $8.7M.
What is the current EBITDA of Cytokinetics? Cytokinetics's last 12-month EBITDA is -$543M.
What is the current EV/Revenue multiple of Cytokinetics? Current revenue multiple of Cytokinetics is 600.9x.
What is the current EV/EBITDA multiple of Cytokinetics? Current EBITDA multiple of Cytokinetics is -9.6x.
What is the current revenue growth of Cytokinetics? Cytokinetics revenue growth between 2023 and 2024 was -57%.
Is Cytokinetics profitable? Yes, Cytokinetics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.